Home Contact News

News

Find out more …

FAQs
News
ROVI up to date
Contact
Filter results
E.g., 22/11/2024
E.g., 22/11/2024
07/11/2024
First nine months 2024 results press release
ROVI ACHIEVED OPERATING REVENUE OF 564.6 MILLION EUROS AND INCREASED ITS GROSS MARGIN BY 4.7 PERCENTAGE POINTS
Download
24/10/2024
ROVI completes the strategic review of its CDMO business
31/07/2024
First half 2024 results press release
ROVI ACHIEVED OPERATING REVENUE OF 329.3 MILLION EUROS AND INCREASED ITS GROSS MARGIN BY 2.8 PERCENTAGE POINTS
Download
11/07/2024
ROVI invests 60 million euros to expand the production capacity of its San Sebastián de los Reyes plant by 31.5%
The Community of Madrid has declared this project to be strategic: it will create 200 new direct jobs for 2027 and raise the plant’s production capacity to 500 million injectables
24/06/2024
ROVI forecasts potential Risperidone ISM® sales of between 200 and 300 million euros globally in upcoming years
20/06/2024
ROVI completes its new Escúzar plant by including a sodium heparin production facility
ROVI reinforces its heparin production capacity
08/05/2024
First three months 2024 results press release
ROVI closes the quarter with operating revenue of 151.2 million euros
Download
25/04/2024
ROVI announces agreement to manufacture pre-filled syringes
Agreement to manufacture pre-filled syringes for a global pharmaceutical company
Download
02/04/2024
ROVI receives the FDA’s approval of Risvan® as a treatment for schizophrenia
Risperidone ISM® is a prolonged-release injectable antipsychotic developed and patented by ROVI for the treatment of schizophrenia in adults
Download

Pages